What’s New in HIV?

Community Symposium: Pre-Exposure Prophylaxis

February 22, 2013
Noon – 1:30pm
MercyCorps Action Center Event Space
45 SW Ankeny St., Portland 97204

Click here to view the presentation.

In July 2012 the Food and Drug Administration approved the use of Truvada, a commonly prescribed HIV antiretroviral medication, for use as pre-exposure prophylaxis (PrEP) against HIV. The topic of PrEP has inspired much discussion and controversy among medical and social service providers, advocacy groups, and the community at large. How effective is PrEP? What is the science behind it? How practical is PrEP at the community level? And what do providers, and people at risk for HIV who are interested in PrEP, need to know?

Join us for a lunchtime panel presentation and discussion, which will include an overview of the science behind PrEP, including clinical trials, a look at how it is being rolled out in other cities, and the resources available to both providers and the community around PrEP.

Panelists:
Joanne Stekler, MD, MPH
Assistant Professor,
University of Washington Division of Allergy & Infectious Diseases
Deputy Director, Public Health
Seattle & King County HIV/STD Program Harborview Medical Center

James Shean
Director, Managed Markets
Gilead Sciences